• Wednesday, August 8, 2018 @ 12:30 pm
  • New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones
  • Financial position strengthened after Q2 close due to issuance of new shares, raising gross proceeds of USD 117.5 million
  • Crenezumab: Phase 3 trial CREAD 2 fully recruited in July 2018; new Phase 2 data analysis provides strong evidence for principal target engagement of Abeta oligomers
  • Selection of small molecules targeting Tau (Tau MorphomersTM) for clinical development in Alzheimer's disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the second quarter and first half ended June 30, 2018.

Read the full media release below.

You may also be interested in